Fractionated microneedle radiofrequency versus botuinum toxin A in primary axillary hyperhidrosis - Trial PACTR201808213089174
Access comprehensive clinical trial information for PACTR201808213089174 through Pure Global AI's free database. This Phase 1 trial is sponsored by Reem Osama Eid and is currently Recruiting. The study focuses on Skin and Connective Tissue Diseases.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to Pan Africa Clinical Trials Registry data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
Reem Osama Eid
Timeline & Enrollment
Phase 1
Jan 01, 1900
Jan 01, 1900
Summary
Primary axillary hyperhidrosis (PAH) is a chronic idiopathic disorder of excessive sweating that affects the axillae. Treatment options include topical application of aluminum chloride, administration of anticholinergic agents and beta-blockers, tap water iontophoresis, botulinum toxin A (BTX-A) injection, excision and suction curettage of sweat glands, or transthoracic endoscopic sympathectomy. Radiofrequency (RF) has recently emerged as a new therapeutic modality in PAH.This study aims at comparing the efficacy and safety of fractionated microneedle radiofrequency with Botulinum toxin A injection in primary axillary hyperhidrosis.
ICD-10 Classifications
Data Source
Pan Africa Clinical Trials Registry
PACTR201808213089174
Device Trial